Skip to content

Mary M Torregrossa

3 papers in the library · 3 citations · publishing 2025-2026

Papers

Sort Most recent Most cited

Envisioning Cannabinoid CB1 Receptor Biased Signaling as a Therapeutic Target for Schizophrenia.

The American journal of psychiatry April 17, 2026 Shih-Hsuan Ku, Sierra J Stringfield, Mary M Torregrossa et al.

The relationship between the endocannabinoid system and the emergence and treatment of schizophrenia-related symptoms continues to be a topic of significant interest within psychiatry. Cannabis is the most widely used recreational drug worldwide, and individuals with schizophrenia use it at a much higher rate than the general population. The shared genetic risk for schizophrenia and cannabis...

Sex specific effects of ketamine, but not other glutamate receptor modulators, on ethanol self-administration and reinstatement of ethanol seeking in rats.

Psychopharmacology April 8, 2025 Megan L Bertholomey, Camryn Forbes, Bryan D McElroy et al. 3 citations

Alcohol use and major depressive disorder are frequently comorbid, with individuals diagnosed with a substance use disorder being nearly three times as likely to have major depression. Poor treatment responses are found for both disorders and are further complicated when they co-occur, underscoring the need for better therapies. One potential candidate is ketamine, which has been shown to have...

Individual differences in the pharmacokinetic profiling of Δ9-THC may be associated with differential motivational effects of Δ9-THC on cognitive performance

Teneisha M. Myers, Noah C. Neverette, Aaron S. Devanathan et al. preprint

Abstract Rationale Cannabis is the most widely used illicit substance in the United States, and its use is increasing with the recent push for legalization and decriminalization, as well as the growing use for medicinal purposes. While cannabis can have positive effects in some individuals, there are potential negative consequences including dependence, psychosis, and cognitive impairments. The...